Call for Comments - ATMP guideline on safety and efficacy follow-up and risk management

News

Call for Comments – ATMP guideline on safety and efficacy follow-up and risk management

March 1, 2018

The revised ATMP guideline on safety and efficacy follow-up and risk management has been released for a 3-month public consultation (deadline of 30^th April).

EMA would be pleased to receive any HTA comments in respect of the post-authorisation safety and efficacy studies’ endpoints.

Please see the links below.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002897.jsp&mid=WC0b01ac058004d5c1

Guideline on safety and efficacy follow up RMP for ATMP: https://docs.eudra.org/webtop/drl/objectId/090142b283cccb2e

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.